(-)-OSU 6162

Bipolar Depression

Göteborg UniversitySmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

28 Active assets in the Bipolar Depression cohort.

Asset / Sponsor	Phase	Rating
Lurasidone NeuroRx, Inc.	Phase 4	A
LITHIUM, ELEMENTAL Dr. Inge Winter	Phase 4	BBB
Seroquel® Dr. Inge Winter	Phase 4	BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Joshua Rosenblat	Phase 4	BBB
LAMOTRIGINE Stony Brook University	Phase 4	BBB

View all 50 →

Same molecule, other indications

(-)-OSU 6162 is also rated in:

acquired aneurysmal subarachnoid hemorrhageDormant

B

Indicative ·

57 / 100

stroke disorderDormant

B

Indicative ·

57 / 100

depressive disorderDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.